Edward F McKone

Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.

Xiaohong Huang, Michael P Boyle, Carla Colombo, 2015, The New England journal of medicine.

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST).

Ying Jiang, Barry Plant, Matthias Griese, 2014, The Lancet. Respiratory medicine.

Ambient air pollution, lung function, and airway responsiveness in asthmatic children.

Antonella Zanobetti, Joel Schwartz, Thomas Lumley, 2016, The Journal of allergy and clinical immunology.

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Matthias Griese, P. Dřevínek, N. McElvaney, 2011, The New England journal of medicine.